Molecular Characterization of Neuroendocrine-like Bladder Cancer.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 31 10 2018
revised: 21 01 2019
accepted: 26 03 2019
pubmed: 7 4 2019
medline: 6 8 2020
entrez: 7 4 2019
Statut: ppublish

Résumé

Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant. Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer (MIBC) have transcriptomic patterns consistent with NE bladder cancer in the absence of NE histology. The clinical implications of this NE-like subtype have not been explored in depth. Transcriptome-wide expression profiles were generated for MIBC collected from 7 institutions and clinical-use of Decipher Bladder. Using unsupervised clustering, we generated a clustering solution on a prospective training cohort (PTC; In the training cohort (PTC), hierarchical clustering using an 84-gene panel showed a cluster of 8 patients (4.6%) with highly heterogeneous expression of NE markers in the absence of basal or luminal marker expression. NE-like tumors were identified in 1% to 6.6% of cases in validation cohorts. Patients with NE-like tumors had significantly worse 1-year progression-free survival (65% NE-like vs. 82% overall; A single-patient classifier was developed that identifies patients with histologic urothelial cancer harboring a NE transcriptomic profile. These tumors represent a high-risk subgroup of MIBC, which may require different treatment.

Identifiants

pubmed: 30952638
pii: 1078-0432.CCR-18-3558
doi: 10.1158/1078-0432.CCR-18-3558
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3908-3920

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

José Batista da Costa (J)

Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Ewan A Gibb (EA)

GenomeDx Inc., Vancouver, British Columbia, Canada.

Trinity J Bivalacqua (TJ)

Department of Urology, Johns Hopkins Medical Institution, Baltimore, Maryland.

Yang Liu (Y)

GenomeDx Inc., Vancouver, British Columbia, Canada.

Htoo Zarni Oo (HZ)

Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

David T Miyamoto (DT)

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Mohammed Alshalalfa (M)

GenomeDx Inc., Vancouver, British Columbia, Canada.

Elai Davicioni (E)

GenomeDx Inc., Vancouver, British Columbia, Canada.

Jonathan Wright (J)

Department of Urology, University of Washington School of Medicine, Seattle, Washington.

Marc A Dall'Era (MA)

Department of Urology, Urothelial Carcinoma Davis Comprehensive Cancer Center, Sacramento, California.

James Douglas (J)

Department of Urology, University Hospital of Southampton, Hampshire, United Kingdom.

Joost L Boormans (JL)

Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands.

Michiel S Van der Heijden (MS)

Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

Chin-Lee Wu (CL)

Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Bas W G van Rhijn (BWG)

Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

Shilpa Gupta (S)

Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.

Petros Grivas (P)

Department of Oncology, University of Washington, Seattle, Washington.

Kent W Mouw (KW)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Paari Murugan (P)

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.

Ladan Fazli (L)

Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Seong Ra (S)

San Diego Pathologist Medical Group, San Diego, California.

Badrinath R Konety (BR)

Department of Urology, University of Minnesota, Minneapolis, Minnesota.

Roland Seiler (R)

Department of Urology, University of Bern, Bern, Switzerland.

Siamak Daneshmand (S)

Urology Department, University of Southern California, Los Angeles, California.

Omar Y Mian (OY)

Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, Ohio.

Jason A Efstathiou (JA)

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Yair Lotan (Y)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.

Peter C Black (PC)

Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. pblack@mail.ubc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH